[Form 4] Kestra Medical Technologies, Ltd. Insider Trading Activity

Rhea-AI Filing Summary

Kestra Medical Technologies director Mary Kay Ladone acquired 10,909 restricted stock units (RSUs) on 09/04/2025, each converting into one common share and scheduled to vest on September 4, 2026, subject to continued service. The filing also reports that 12,994 restricted common shares were automatically converted in connection with the issuer's initial public offering from previously held Class A Common Units granted October 7, 2024. Those converted restricted shares vest in three tranches: 4,331 on October 7, 2025; 4,331 on October 7, 2026; and 4,332 on October 7, 2027. The form is signed by the reporting person and identifies her as a director.

Positive

• 10,909 RSUs granted that convert to one common share each and vest on September 4, 2026, aligning director incentives with long-term performance
• 12,994 restricted common shares converted from pre-IPO Class A Common Units, with a clear vesting schedule across October 7, 2025, October 7, 2026, and October 7, 2027

Negative

• None.

Insights

Financial Analyst

TL;DR: Insider received RSUs and converted restricted shares with multi-year vesting, signaling routine executive equity compensation.

The transaction is a standard equity-compensation event for a director rather than a market sale or open-market purchase. The 10,909 RSUs vest one year from grant, aligning the reporting persons incentives with shareholder value over that period. The 12,994 converted restricted common shares stem from an IPO-related unit conversion and retain scheduled vesting across 20252027, which staggers potential share dilution. There is no cash consideration or market disposition disclosed in this filing.

Corporate Governance Expert

TL;DR: Vesting schedules and conversion from IPO units reflect typical governance and retention practices for newly public companies.

The filing documents standard retention-focused grants: time-based RSUs and conversion of pre-IPO restricted units into restricted common shares with multi-year vesting. These arrangements are commonly used to retain directors and align long-term interests. The reporting person is identified as a director, and the filing includes the requisite certification signature. No departures, exercised options, or sales are reported, limiting immediate governance concerns.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ladone Mary Kay

(Last) (First) (Middle)

C/O KESTRA MEDICAL TECHNOLOGIES, LTD.

3933 LAKE WASHINGTON BLVD NE, SUITE 200

(Street)

KIRKLAND WA 98033

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	09/04/2025		A		10,909(1)	A	(1)	23,903(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported securities represent restricted stock units ("RSUs") which each entitle the Reporting Person to receive one common share of the Issuer. The RSUs will vest on September 4, 2026, subject to the Reporting Person's continued service through such date.

2. Includes 12,994 restricted common shares of the Issuer that were automatically converted in connection with the Issuer's initial public offering from Class A Common Units of West Affum Holdings, L.P. previously held by the Reporting Person which were originally granted on October 7, 2024. The restricted common shares vest into common shares of the Issuer. 4,331 restricted common shares will vest on October 7, 2025, 4,331 restricted common shares will vest on October 7, 2026 and 4,332 restricted common shares will vest on October 7, 2027.

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ Mary Kay Ladone	09/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Kestra Medical Technologies (KMTS) director Mary Kay Ladone acquire on 09/04/2025?

The filing reports acquisition of 10,909 restricted stock units (RSUs) on 09/04/2025, each converting into one common share and vesting on September 4, 2026.

How many restricted common shares converted in connection with KMTS's IPO and what is their vesting schedule?

12,994 restricted common shares were converted from Class A Common Units and vest as follows: 4,331 on 10/07/2025, 4,331 on 10/07/2026, and 4,332 on 10/07/2027.

Is Mary Kay Ladone an officer or director at KMTS according to the Form 4?

The Form 4 identifies Mary Kay Ladone as a Director of Kestra Medical Technologies, Ltd.

Were any open-market sales or purchases reported in this Form 4 for KMTS?

No open-market sales or purchases are reported; the form documents RSU acquisitions and conversions of restricted shares rather than market trades.

When do the 10,909 RSUs reported by KMTS vest?

The 10,909 RSUs vest on September 4, 2026, subject to the reporting person's continued service through that date.